Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.31 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86873 | 0.94 | HRH1 (0.38) | HRH1GABRPGABRDGABRA1TSHR | |
| SCHEMBL19046616 | 0.92 | HRH1 (0.37) | HRH1ALDH1A1 | |
| SCHEMBL19046623 | 0.92 | HRH1 (0.37) | HRH1ALDH1A1 | |
| SCHEMBL20327774 | 0.92 | HRH1 (0.37) | HRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL77301 | 0.92 | HRH1 (0.37) | HRH1 | |
| SCHEMBL19046615 | 0.92 | HRH1 (0.37) | HRH1ALDH1A1 | |
| SCHEMBL3105213 | 0.92 | HRH1 (0.37) | HRH1ALDH1A1 | |
| SCHEMBL8018672 | 0.91 | HRH1 (0.42) | HRH1GABRPGABRDGABRA1TSHR | |
| Hydrochloric Acid SCHEMBL2775809 | 0.89 | HRH1 (0.35) | HRH1ALDH1A1 | |
| SCHEMBL21165379 | 0.88 | TSHR (0.39) | HRH1GABRPGABRDGABRA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282486-A2 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4194451-A1 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022087125-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN | ARVINAS OPERATIONS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| CN-109640975-A | The combination of histamine-3-receptor inverse agonist and acetylcholinesterase inhibitor | 苏文生命科学有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-106573925-A | Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride | 苏文生命科学有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | HRH1 3198/4885HRH3 2869/4885GABRP 1078/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | HRH1 1190/4885HRH3 1365/4885GABRP 2489/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | HRH1 1190/4885HRH3 1365/4885GABRP 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.